Topics

KOL Perspectives: Rituximab Use in Lupus [Report Updated: 02072018] Prices from USD $2125

04:41 EST 29 Nov 2018 | BioPortfolio Report Blog

KOL Perspectives: Rituximab Use in Lupus


Summary


This KOL Insight briefing focuses on KOLs views of Rituximab Use in Lupus.


Questions topics

Current future use of RTX in lupus

Views on RTX's Phase II/III EXPLORER trial reanalysis

Opinion on data demonstrating that RTX is effective for the management of refractory SLE

Views on data from the Phase II SYNBIoSe study assessing RTX + BEL combination therapy

Lupus patients most suitable for RTX + BEL combination therapy

Use of RTX + BEL combination therapy


Key Highlights


Most US KOLs stated that future launch of biosimilar RTX will have no impact on their overall use of RTX, but uptake will depend on price

Most KOLs highlighted that the level of background medication used in the EXPLORER trial was too high and consequently impeded results

Most KOLs flagged that payers may be a barrier to combination therapy use, especially given the lack of approval for RTX in lupus.


Scope


The insight briefing is based on Sociable Pharma's analysis of primary research with our Lupus key opinion leaders KOLs.


In total, we conducted interviews with 10 KOLs

5 Europebased 5 N. Americabased

Interviews performed during Q2 2018


KOL data is analyzed to produce

Charts summarizing KOL opinions

Chart callouts of key information details

KOL quotes

Summary of KOL reporting trends

Insight from Sociable Pharma's analysts


Reasons to buy


Combines Qualitative semiquantitative insight from key opinion leaders on Rituximab Use in Lupus

Includes insight recommendations from our diseasespecific healthcare analysts

Utilizes independent expert viewpoints to validate the impact of new clinical data emerging trends on management of Lupus

Provides costeffective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Original Article: KOL Perspectives: Rituximab Use in Lupus [Report Updated: 02072018] Prices from USD $2125

NEXT ARTICLE

More From BioPortfolio on "KOL Perspectives: Rituximab Use in Lupus [Report Updated: 02072018] Prices from USD $2125"

Quick Search

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Lupus
Lupus is a complex and poorly understood condition that affects many parts of the body and causes symptoms ranging from mild to life-threatening. There are several types of lupus. The main types are: discoid lupus erythematosus drug-induced lu...

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...